FDA 483 - Covance Clinical Research Unit, Inc. - June 07, 2019

An FDA inspection of Covance Clinical Research Unit, Inc. in Dallas, TX, revealed a significant issue with record retention. The firm failed to maintain individual blinding codes for a clinical trial for the required two-year period, destroying them prematurely. This indicates a serious lapse in regulatory compliance regarding document control for clinical investigations.